Argent BioPharma's Strategic Acquisition: Aiming for a $100M Valuation with AusCann Group Assets Argent BioPharma is set to acquire key assets from AusCann Group, enhancing its clinical pipeline and European presence. The move anticipates a company valuation of $100M.

Argent BioPharma's Strategic Acquisition: Aiming for a $100M Valuation with AusCann Group Assets #Australia #Sydney #Argent_BioPharma #AusCann_Group #Neuvis